Table 4.
The top 2 differentially methylated CpG sites associated with COPD
| CpG Site | Gene | Mean Difference Methylation | FDR Adjusted p-value | Logistic regression model for risk factors | |
|---|---|---|---|---|---|
| Adjust β (95% CI) | p-value | ||||
| chr4:75310999 | AREG | 0.46% | 0.011 | 71.34(1.79, 140.9) | 0.044 |
| chr4:75310908 | AREG | 0.45% | 0.008 | 49.92(−3.04, 102.88) | 0.065 |
| chr3:112281685 | ATG3 | −2.61% | 0.037 | −8.45(−16.32, −0.59) | 0.035 |
| chr3:112281810 | ATG3 | −1.83% | 0.037 | − 12.00(−23.35, − 0.64) | 0.038 |
| chr6:108882977 | FOXO3 | −9.09% | 1.68855E-05 | −8.83(− 14.65, −3.00) | 0.003 |
| chr6:108882982 | FOXO3 | −9.04% | 3.652E-05 | −8.52(−14.26, −2.78) | 0.004 |
| chr20:32273763 | E2F1 | −3.45% | 0.008 | −21.5(−43.20,0.19) | 0.052 |
| chr20:32274387 | E2F1 | 2.72% | 0.014 | 20.01(4.35, 35.66) | 0.012 |
| chr1:32757717 | HDAC1 | 0.67% | 0.026 | 29.61(0.34, 58.89) | 0.047 |
| chr1:32757818 | HDAC1 | −0.41% | 0.027 | −50.71(−97.74, −3.65) | 0.035 |
| chr1:163292017 | NUF2 | −0.42% | 0.011 | −97.07(− 171.02, −23.11) | 0.10 |
| chr1:163291916 | NUF2 | 0.33% | 0.005 | 67.50(−5.96, 140.98) | 0.072 |
| chr16:55514378 | MMP2 | −1.66% | 0.013 | −14.01(−27.68, −0.34) | 0.045 |
| chr16:55514466 | MMP2 | −1.50% | 0.023 | −16.59(− 33.14, −0.05) | 0.049 |
| chr19:41859656 | TGFB1 | 1.82% | 0.033 | 11.88(1.38, 22.37) | 0.027 |
| chr19:41859677 | TGFB1 | −1.67% | 0.01 | −34.21(−60.97, − 7.45) | 0.012 |
| chr17: 7591645 | TP53 | −3.83% | 0.001 | 139.19(18.45, 257.93) | 0.024 |
| chr17:7590743 | TP53 | −0.68% | 0.026 | 209.32(80.13, 338.51) | 0.001 |
Differential methylation analysis was conducted between COPD patients and controls in blood samples from a total of 105 subjects. The method of Benjamin Hochberg was used to control the false discovery rate (FDR), p < 0.05; Adjusted β were derived from Binary logistic regression analysis. These factors were adjusted in the logistic regression analysis: age, smoking history and work environment and outdoor pollution